Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

UBS initiated coverage with a ‘Buy’ rating and set a $1,250 price target, citing confidence in Lilly’s obesity execution.

Mysterious cat Nimbus Pronos has tipped Nigeria to beat Mozambique in their AFCON 2025 Round of 16 clash, boosting confidence ...

Nimbus Group has secured its first order from Japan for its flagship model, the Nimbus 495 Flybridge. The order was placed by ...

AI platform partners with businesses across Hawaii, New York, and California to address $2.6 trillion productivity gap; founder's research ...

India's Dr Reddy's Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed ...

Preview | Day 1 | Day 2 + Amendment: Helgo vs Hunter | Day 3 | Day 4 Preview Preview | Day 1 | Day 2 | Day 3 2025 By the Numbers (PDF) Race to the 2026 WTA Finals - Qualification Rules (PDF) Career ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

From city streets to rural trails, here are the best pairs for any locale—as recommended by runners who’ve logged the miles.